Movatterモバイル変換

[0]ホーム

Jump to content

Pritumumab

中文

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Pritumumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	vimentin
Clinical data
ATC code	none
Identifiers
CAS Number	499212-74-7^N
ChemSpider	none
UNII	Z6Q90D1G53
Chemical and physical data
Formula	C₆₄₄₀H₉₉₆₈N₁₇₀₈O₂₀₁₆S₄₂
Molar mass	144923.04 g·mol⁻¹
^NY (what is this?) (verify)

Pritumumab (PTB) is ahuman monoclonal antibody targeted againstglioma.^[1] It works by binding to the ecto-domain ofvimentin on the surface of cancer cells.^[1]^[2] developed byNascent Biotech.

It is in clinical trials for the treatment ofglioma.^[3]^[4] TheFDA grantedorphan drug designation in 2015.

The target ofPritumumab, cell surface vimentin, has been implicated in the replication of coronavirus, specifically in Severe acute respiratory syndrome coronavirus (SARS-CoV).^[5]

PTB has been proposed as a potential treatment for COVID-19 and related Viral Infections.^[6]

References

[edit]

^^a ^bBabic I, Nurmemmedov E, Yenugonda VM, Juarez T, Nomura N, Pingle SC, Glassy MC, Kesari S (February 2018). "Pritumumab, the first therapeutic antibody for glioma patients".Human Antibodies.26 (2):95–101.doi:10.3233/HAB-170326.PMID 29036806.S2CID 3266191.
^"International Nonproprietary Names for Pharmaceutical Substances (INN)"(PDF).WHO Drug Information.18 (1). 2004. Archived fromthe original(PDF) on 11 February 2012.
^"Nascent Biologics Proven Cancer Cure Back in the Hands Of U.S. Inventor After 27 Years In Japan". Nascent Biologics. 1 October 2009. Archived fromthe original on 2011-07-14.
^Clinical trial numberNCT04396717 for "Safety Study of Pritumumab in Brain Cancer" atClinicalTrials.gov
^Yu YT, Chien SC, Chen IY, Lai CT, Tsay YG, Chang SC, Chang MF (January 2016)."Surface vimentin is critical for the cell entry of SARS-CoV".Journal of Biomedical Science.23: 14.doi:10.1186/s12929-016-0234-7.PMC 4724099.PMID 26801988.
^"Race For Vaccine Intensifies As COVID-19 Second Wave of Outbreaks Threatens".Financialnewsmedia.com. 17 June 2020.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Atezolizumab (+hyaluronidase) Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase,+relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab^# Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan /+emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Thisantineoplastic orimmunomodulatory drug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pritumumab&oldid=1188064451"

Categories:

Hidden categories:

[8]ページ先頭